Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemorrhage is defined as the escape of blood from the circulatory system due to vascular injury or impaired hemostatic mechanisms (StatPearls, 2023). It is a clinical condition and physiological event rather than a specific molecular target such as a protein, enzyme, or receptor. In a pharmacological context, 'hemorrhage' is an indication for treatment rather than the target itself, with therapeutic interventions aimed at biological components of the coagulation cascade or fibrinolytic system to stop blood loss (NIH, 2022). Drugs such as tranexamic acid target plasminogen to prevent clot breakdown, while others replace specific clotting factors to restore the body's ability to form stable thrombi (PubMed, 2021). Because it lacks a specific molecular structure or binding site, it is classified as an incorrect entry for a drug target database.
Pharmacological agents used in the management of hemorrhage typically act as antifibrinolytics (inhibiting plasminogen activation), procoagulants (replacing deficient clotting factors), or vasopressin analogs to promote platelet adhesion and factor release.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemorrhage.